Your browser doesn't support javascript.
loading
Orbital trochleitis: Literature review.
Collado Sánchez, L; Munuera, I; Rodrigo Sanjuán, M J; Garcia-Martin, E.
Afiliação
  • Collado Sánchez L; Universidad de Zaragoza, Biotech Vision SLP Empresa Spin off de la Universidad de Zaragoza, Instituto de investigación Sanitaria Aragón, Zaragoza, Spain.
  • Munuera I; Universidad de Zaragoza, Biotech Vision SLP Empresa Spin off de la Universidad de Zaragoza, Instituto de investigación Sanitaria Aragón, Zaragoza, Spain; Departamento de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Rodrigo Sanjuán MJ; Universidad de Zaragoza, Biotech Vision SLP Empresa Spin off de la Universidad de Zaragoza, Instituto de investigación Sanitaria Aragón, Zaragoza, Spain; Departamento de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Garcia-Martin E; Universidad de Zaragoza, Biotech Vision SLP Empresa Spin off de la Universidad de Zaragoza, Instituto de investigación Sanitaria Aragón, Zaragoza, Spain; Departamento de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: egmvivax@yahoo.com.
Article em En | MEDLINE | ID: mdl-38901607
ABSTRACT
Trochleitis is clinically and/or radiologically evidenced inflammation of the trochlea or orbital pulley. Clinically it is characterized by pain and hypersensitivity in the superomedial orbital angle, which is increased or triggered by direct palpation of the area and/or eye movements. During the REM (rapid eye movements) phase of sleep, patients with trochleitis suffer from nocturnal micro-awakenings that impede their rest, and pain is often associated with visual symptoms (diplopia or Brown's syndrome). The lack of common guidelines for diagnosis and treatment of this disease, its low prevalence and the lack of knowledge of the different entities associated with trochlear pain, leads to underdiagnosis or misdiagnosis. It is essential to know the characteristics of this pathology and to diagnose it correctly, differentiating it from other trochlear pain entities, in order to be able to carry out an adequate therapeutic and prognostic approach. The lack of consensus on the therapeutic protocol means that various treatments are used, in different order and often with a combination of several without a firm scientific basis. This comprehensive review of previous studies concludes that nonsteroidal anti-inflammatory drugs (NSAIDs) achieve an overall complete cure rate of 77%, although this rate decreases to 30% in case of motility restriction or diplopia. Intratrochlear corticosteroid injection achieves an overall complete cure rate of 86%, even in the worst prognosis trochleitis, being the only effective option in NSAID-refractory trochleitis and currently being questioned as the first treatment option.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Arch Soc Esp Oftalmol (Engl Ed) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Arch Soc Esp Oftalmol (Engl Ed) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha